PTP4A3 and cancer: PRL-3 expression is correlated with disease progression and poor survival[3-8], and its antibody was shown to dramatically inhibit metastatic tumor formation in human ovarian cancer cells[9], therefore it had been deemed as a potential therapeutic target for the treatment of cancer[10].